Epigral aims to grow in 20%, expecting more than PY28 income

The largest special chemicals aimed to grow at 20% of the year old and ready to exceed the income of the income with FY2028, a company official said on Saturday.
A limited need for receivables and double production skills will serve as key carlysts in the Epigril, Chairperson, the Executive Director, the Executive Director, Director, Managinator, said the Executive Director; , said the executive director, the Executive Director, the Executive Director, the Executive Director, the Executive Director, said Director, the Executive Director, said Director, said Directories said. The Director The Executive Director, said Director, said Director, Director, Managinarine, said Director, said Director, said Director, said Director, said the Executive Director;
The income of a combined company of 2023-24 stopped at RS 1936 crore.
Epigral reported the Epigpar to be more than 37% of RS 1,934. CRORE in the first nine months of 2024-25 compared to RS 1,45 Crore last year, according to exchange exchange.
The Derivatives & Specialty Business contributed 54% to Topline.
According to a Sunidhi research report, Epigril income is expected to be over Rs 3,500 crore by FY27. Another solid EMKay of research in its report says that it expects Rs 3,800 Crore money with FY27 with a 26 percent of Bibda Mart.
The company doubles its polyvinyl chloride (CPVC
With this new CAPEX, the use of chlorine captured will improve and will also make higher contributions to the acquisition and special products. CPVC is one of the important ingredients in pipes.
“We expect our volumes on various projects that we will receive for 3 to 5 years thus creating the number of our participants.” Patel said.
“We focus on the expensive return of the backdrop and additions to the ongoing transfusion products. Our investment in the search center will also strengthen our existing chemicals and add molecules to chlorolines.” Add.
In the third quarter of FY25, the company has reported more than two jumping in Rs 103.63 crore compared to Rs 49 Crore last year.
The income increased from Rs 649 crore in a quarter of the december from RS 474 crore in the year of the past.